isomethyleugenol has been researched along with Anti-MuSK Myasthenia Gravis in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (33.33) | 18.7374 |
| 1990's | 1 (33.33) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (33.33) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Du, J; Fang, TK; Yan, CJ | 1 |
| Adams, R; Drachman, DB; Kuncl, RW; Lehar, M | 1 |
| Bartfeld, D; Fuchs, S | 1 |
3 other study(ies) available for isomethyleugenol and Anti-MuSK Myasthenia Gravis
| Article | Year |
|---|---|
CTLA-4 methylation regulates the pathogenesis of myasthenia gravis and the expression of related cytokines.
Topics: Acetylcholinesterase; Adolescent; Adult; Aged; Animals; Child; CTLA-4 Antigen; Cytokines; Disease Models, Animal; Female; Humans; Male; Methylation; Middle Aged; Myasthenia Gravis; Rats, Inbred Lew; T-Lymphocytes, Regulatory; Up-Regulation; Young Adult | 2018 |
3-Deazaadenosine: a therapeutic strategy for myasthenia gravis by decreasing the endocytosis of acetylcholine receptors.
Topics: Animals; Cells, Cultured; Depression, Chemical; Endocytosis; In Vitro Techniques; Kinetics; Methylation; Muscle Proteins; Muscles; Myasthenia Gravis; Rats; Receptors, Cholinergic; Tubercidin | 1993 |
Specific immunosuppression of experimental autoimmune myasthenia gravis by denatured acetylcholine receptor.
Topics: Acetylcholine; Animals; Antibody Specificity; Autoantibodies; Immunosuppression Therapy; Immunotherapy; Methylation; Myasthenia Gravis; Oxidation-Reduction; Rabbits; Receptors, Cholinergic | 1978 |